Category: Analysis - Psychedelic Alpha

New: Explore the psychedelic pipeline via our Q3'25 🎯 Bullseye Charts.

Read more about the article UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

Post published:September 19, 2025
Post category:Analysis News Pα+

Read more about the article Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

Post published:September 16, 2025
Post category:2024 Year in Review Analysis

Read more about the article Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Post published:September 8, 2025
Post category:Analysis News Pα+

Read more about the article BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

Post published:September 4, 2025
Post category:Analysis News

Read more about the article Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Post published:September 3, 2025
Post category:Analysis News Pα+

Read more about the article AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

AbbVie to Acquire Gilgamesh’s Bretisilocin for Up to $1.2B

Post published:August 25, 2025
Post category:Analysis News Pα+

Read more about the article Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

Norway Approves Public Funding for Generic Ketamine in Treatment-Resistant Depression

Post published:August 25, 2025
Post category:Analysis News Pα+

Read more about the article Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression

Reunion Neuroscience Posts Strong Phase 2 Results for RE104 in Postpartum Depression

Post published:August 18, 2025
Post category:Analysis News Pα+

Read more about the article One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Post published:August 15, 2025
Post category:Analysis Pα+

Read more about the article From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Post published:August 12, 2025
Post category:Analysis Interviews

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.